Background-The precise site of intestinal permeability changes in patients with coeliac and inflammatory bowel disease is
unknown. Aims-To design a non-invasive technique for the localisation ofaltered gastrointestinal permeability to slchromium labelled EDTA (51CrEDTA). The method depends on comparing and defining concentration/ time profiles in serum of a series of simultaneously ingested indicators with a well defined absorption site (3-0-methyl-D-glucose (jejunal indicator), 57cobalt labelled vitamin B12 (ileal indicator), and sulphasalazine (caecal-colonic indicator)) in relation to simultaneously ingested 51CrEDTA. Subjects-Five normal controls, six patients with untreated coeliac disease, five with Crohn's ileitis, and five with pan-ulcerative colitis underwent study, which entailed the simultaneous ingestion of the above four test substances followed, during the next 24 hours, by timed serial collection of urine and serum for marker analysis.
Results-Urinary excretion of 51CrEDTA was significantly increased in all patient groups. Analysis of serum appearances and profiles of the markers suggested that the increased intestinal permeation of 51CrEDTA took place in the diseased jejunum in patients with coeliac disease, predominantly in the ileum in Crohn's disease and in the colon in the patients with pan-ulcerative colitis. Conclusion-A new non-invasive technique has been assessed that permits the localisation of the site of permeability changes with the gastrointestinal tract.
Non-invasive tests of intestinal permeability are widely used to screen for small intestinal disease and assess the importance of the intestinal barrier function in the aetiology and pathogenesis of intestinal and systemic disease.1 2 Choice of test procedure for assessing intestinal permeability depends on clinical and experimental circumstances. In general there is good agreement between results obtained with the five hour differential urinary excretion of lactulose/L-rhamnose (or lactulose/mannitol) and the 24 hour urinary excretion of 51chromium labelled EDTA (51CrEDTA).2-4 After ingestion the uptake of test sugars, which are subjected to rapid bacterial degradation after reaching the caecum, being largely from the small intestine is not affected by colonic pathology. In the case of 51CrEDTA given by itself, distinction between small intestine and colonic contributions to the 24 hour urinary excretion is uncertain.
In an attempt to discriminate between changes in small intestinal and colonic permeability Jenkins et al 5 administered lactulose, L-rhamnose, and 51CrEDTA together and measured timed excretions of these markers in urine. The ratio of urinary lactulose/L-rhamnose during the first five hours provided an index of small intestinal permeability, and the total 24 hour urinary excretion of 51CrEDTA, less that of lactulose (as % of doses) served as an index of colonic permeability. 5 The results showed that the colon was likely to be the site of increased intestinal permeation of 51CrEDTA in patients with active panulcerative colitis,5 and others have found similar changes after abdominal radiation.6 Nevertheless the technique does not permit the additional differentiation between an upper and lower small intestinal site of altered intestinal permeability that is possible using the technique we now report, based on serum concentration/time profiles after ingestion of 51CrEDTA together with 3-0-methyl-D-glucose, 57Cobalt labelled The reliability of 'first appearance in serum' to indicate arrival at a particular level in the intestine requires that mucosal uptake of the markers used is not unduly delayed and takes place at a similar rate. The rates of mucosal permeation for 57CoVitBI2 and sulphapyridine have been assessed previously.8 9 12 To assess the relative mucosal permeation rates of 3-0-methyl-D-glucose and 51CrEDTA in the same intestine four patients (males, mean age 38 years, range 32-40) with the irritable bowel syndrome, undergoing routine gastroduodenoscopy, had a test solution containing 3-0-methyl-D-glucose (2.5 g) and 51CrEDTA (1 mCi) in 50 ml water instilled directly into the duodenum. Serum samples taken before, and at five minute intervals for a period of 30 minutes after instillation, were assayed for these markers.
No subject had recently had alcohol (within seven days), non-steroidal anti-inflammatory drugs or other drugs (within six months) known to affect intestinal integrity.2 These studies were approved by the Harrow and Camberwell Health Authority Ethical Committees and all subjects gave informed consent.
Procedure All subjects were admitted to a metabolic research ward for the study. They fasted from 12 hours before the test until the study was complete. Throughout the studies they lay supine except for toilet purposes. At 7 am on the day of the test subjects received an intramuscular injection of cyanocobalamine (1 mg in 1 ml, Glaxo, UK) to saturate vitamin B12 receptors and hence to facilitate the detection of 57CoVitBI2 in serum. An indwelling intravenous cannula was placed into the antecubital veins of both arms, one being used for intravenous injection and fluid replacement (started at 11 am; 3 litres of glucose-saline with 60 meq potassium given over 18 hours) and the other for obtaining blood samples for analyses.
At 7.45 am subjects swallowed two capsules containing human intrinsic factor (Amersham International, Amersham, Buckinghamshire, UK and Frost Laboratories, Quebec, Canada) with 20 ml of water. At exactly 8 am patients received 10 ml of sterile saline intravenously containing 100 ,uCi 99mtechnetium diethylenetriaminopenta acetate (99mTcDTPA) (3.7 MBq, Amersham International) over a period of 10 seconds while drinking the 100 ml test solution (within one minute), which contained: 3-0-methyl-D-Glucose (2.5 g, Sigma,
Poole, Dorset, UK), 57CoVitB12 (5 , uCi, 19 kBq, Amersham International), sulphasalazine (2.0 g, Syrup, Pharmacia, Milton Keynes, UK), 51CrEDTA ( 1  2  3  4  5  1  2  3  4  5  6  1  2  3  4  5  1  2  3  4   5   3-0-m-D-glucose  20  10  15  10  5  10  30  10  5  60  20  5  10  10  10  10  5  15  10  10  10  51CrEDTA  30  60  60  60  25  5  30  20  5  60  10  10  15  10  60  15  60  60  10  15  20  57CoVitB12  240 300 300 180 300 120 240 360 180 300 180 300 240 120 240 300 300 240 180 240 360  Sulphapyridine  180 180 240 300 300 180 240 360 300 420 240 180 240 120 240 420 360 240 240 120 In the main study serum creatinine was normal in all subjects. The Table shows that glomerular filtration rates varies from 94 ml/min to 138 ml/min, which is within the reported normal physiological range for these age groups, and there were no significant difference between the study groups.
The Table shows (0 31)%, range 1*46 to 3.15%. Figure 2 shows the permeation profile from the patients with untreated coeliac disease. Comparison with normal subject response (Fig 1) shows that there are no significant dif- Figure 3 shows the permeation profile from the patients with Crohn's ileitis. There is an early rise of 51CrEDTA (in two cases indistinguishable from that seen in the patients with coeliac disease), but a second increase ranging from 0.06 to 0.21% dose/litre and coinciding with the appearance of the 'ileal' and 'caecal' markers in the serum, was also evident in four of five patients. Unlike the normal and coeliac disease groups, significant levels of 51 CrEDTA were detected in serum of the Crohn's ileitis group throughout the test. The 24 hour urinary 51CrEDTA excretion, 5.32 (0.98)%, range 2-94 to 831%, was significantly greater (p<001) than in normal subjects. Figure 4 shows the permeation profile from patients with pan-ulcerative colitis. The early peak values of 51CrEDTA in serum at one hour did not differ significantly from the normal group (one patient had increased early serum values of 51CrEDTA similar to that in coeliac disease). There was, however, a clear increase in 51CrEDTA values two to five hours after the appearance of the 'ileal' and 'caecal' markers, which was evident in all the patients. The 24 hour urinary 51CrEDTA excretion, 5.97 (1.05)%, range 3.06 to 8.85%, was significantly greater than in normal subjects (p<0.01).
Presenting the mean permeation profiles can be slightly misleading because of the variation in transit times, etc. In particular the difference between individual cases of Crohn's disease and ulcerative colitis were sharper than Figures  3 and 4 would imply. Figure 5 shows representative traces from a patient with Crohn's ileitis and ulcerative colitis where the increase in serum values of 51CrEDTA clearly coincides with the appearance of the 'ileal' and 'caecal' markers in Crohn's disease and comes distinctive later in ulcerative colitis.
Discussion
This paper describes a new technique that was designed to assess the site of permeability changes within the gastrointestinal tract. The results suggest that the site of increased intestinal permeability in coeliac disease, Crohn's disease, and pan-ulcerative colitis is the diseased intestine itself. In the context of this study there are, however, a number of factors that need to be considered when interpreting the data. In particular the use of the time of appearance of indicator substances in serum and the permeation profiles is determined by a number of variables that could affect the results. Figure 1 .
subjected to hepatic metabolism. It is the rate of permeation across the intestine that determines how accurately the 'first appearance' of the markers in serum represents the 'head' of the test solution in each part of the intestine. There was no discrepancy between the rate of appearance of 3-0-methyl-Dglucose and 51CrEDTA after duodenal instillation in normal subjects and previous studies have also shown that sulphapyridine appears within six minutes of caecal instillation.9 Our results, however, show an inconsistency between the time of appearance of the 'ileal' and 'caecal' markers in serum and in six cases sulphapyridine appeared before the 'ileal' marker. These findings are consistent with reports of a 30-240 minute delay for the appearance of vitamin B12 after ileal instillation,8 12 which is probably due to intracellular processing of the vitamin B12 intrinsic factor complex.16 17 The 'first appearance' of 57CoVitBI2 in serum is therefore likely to overestimate the time it takes for the 'head' of the test solution to reach the ileum. In both normal subjects and patients with ulcerative colitis there is a significant lag time between the serum detection of 3-0-methyl-Dglucose and 51CrEDTA whereas the appearance of both markers in the serum after direct instillation into the duodenum is both rapid and simultaneous. This might suggest that the main site of permeation of 51CrEDTA after ingestion is normally somewhat distal to that of 3-0-methyl-D-glucose, but it might also be that the uptake of 51CrEDTA on reaching the duodenum in the 'head' of the test solution gives serum values that are initially below the detection limits of the gamma counting. Reliable detection of 51CrEDTA in serum might therefore be delayed until the bulk of the test solution had entered the jejunum.
In patients with untreated coeliac disease the appearance of 5 CrEDTA in serum coincided with and peaked at the same time as 3-0-methyl-D-glucose suggesting that there was increased intestinal permeability in the upper small intestine. These findings are consistent with results of studies in coeliac disease, which indicate increased in vitro permeation of various markers'8 19 and with freeze fracture studies,20 which demonstrate decreased strand number and depth in the intercellular junctions. The results in Crohn's disease were not as clear cut. A similar pattern of increased permeation of 5'CrEDTA coinciding with that of 3-0-methyl-D-glucose was found in two patients. One of these and the remaining three patients had peak values of 51CrEDTA coinciding with the appearance of the 'ileal' and 'caecal' markers. As this rise (seen in Fig   5) in the serum values of 51CrEDTA occurred much earlier than in the patients with ulcerative colitis it seems likely that it represents increased ileal permeability to 51CrEDTA. Increased 'jejunal' permeability in some patients with Crohn's ileitis is consistent with in vitro findings of increased permeability in apparently unaffected jejunal mucosa of patients with Crohn's disease. 19 The initial serum profiles of 5'CrEDTA in pan-ulcerative colitis were indistinguishable from normal subjects in four of five cases. The increase in serum 51CrEDTA in the four patients occurred somewhat later than in the patients with Crohn's ileitis, occurring after the appearance of the 'ileal' and 'caecal' indicators. This suggests that the inflamed colonic mucosa is the site of increased permeation of 51CrEDTA in ulcerative colitis as suggested by Jenkins et al.5 This is also in keeping with studies showing increased permeation of 51CrEDTA after rectal administration in ulcerative colitis. 2' 22 Indeed, the permeation of 51CrEDTA correlated significantly with histopathological assessment of disease activity in these patients. 2' In summary a new non-invasive technique has been assessed that permits the localisation of the site of altered permeability with the gastrointestinal tract. The principle of the method seems to be generally applicable to other test substances than permeability probes, but there is a need to identify an equally site specific 'ileal indicator' to that of vitamin B12, which does not have the delayed rate of absorption.
